Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD ...
The Pharma Letter1d
Phase IV Ingrezza data move focus from sales outlook
Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...
Neurocrine reports patient-reported outcome data from KINECT-PRO study
Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...
FierceBiotech3d
Harbour offshoot pens $395M biobucks deal for preclinical rival to Neurocrine's Crenessity
With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at A replay of the webcasts will be available on the website approximately ...
Neurocrine price target lowered to $183 from $191 at JPMorgan
JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated ...
Equities Analysts Issue Forecasts for NBIX Q4 Earnings
Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects ...
Barron's6d
Neurocrine Biosciences Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...